Celebrating 13 Years of Nonprofit Independence
Menu
Shedding Light on the Risks
& Benefits of Medications 
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Menu
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

GLP-1s

Between 2019 and 2024, the use of GLP-1 drugs to treat overweight or obesity increased nearly 587%. Originally developed to treat diabetes, GLP-1s such as Ozempic and Mounjaro later gave rise to obesity-only focused counterparts, including Wegovy (approved in 2021) and Zepbound (approved in 2023). As of this writing, about 1 in 8 adults (12%) say they’ve taken a GLP-1 drug, even while data about their long-term use remains limited — particularly concerning weight loss. 

MedShadow is committed to covering new iterations of these drugs, as well as emerging research and potential side effects. Stories in this series were accurate and complete at the time of publication.

Are you, or have you ever been, on a GLP-1 and have a story to share? Email Jessica@medshadow.org

RECOMMENDED:
FDA SIDE EFFECTS UPDATE: Antidepressants, Stimulants May Interfere With Parkinson’s Test
FDA SIDE EFFECTS UPDATE: Antidepressants, Stimulants May Interfere With Parkinson’s Test
Read More
FDA SIDE EFFECTS UPDATE: Seizure and Vitamin Deficiency Risk for Parkinson’s Drugs
FDA SIDE EFFECTS UPDATE: Seizure and Vitamin Deficiency Risk for Parkinson’s Drugs
Read More
FDA SIDE EFFECTS UPDATE: Children’s Zyrtec Linked to Withdrawal Itching, Finasteride Tied to Suicidal Thoughts, and More
FDA SIDE EFFECTS UPDATE: Children’s Zyrtec Linked to Withdrawal Itching, Finasteride Tied to Suicidal Thoughts, and More
Read More
Want to feel more informed & empowered about medication decisions and whole-health alternatives?

No pharma ads. No political bias. Just straight up strong journalism.

Delivered directly to your inbox.

What is unbiased drug-safety journalism worth to you?

We think it’s invaluable — and hope you agree. Our work is made possible by donations from readers like you.

Donate to MedShadow
trigger

What is Unbiased Drug-Safety Journalism Worth to You?

We think it’s invaluable — and hope you agree. Our journalism is made possible by donations from readers like you.

As a nonprofit, we don’t take a dime from pharmaceutical or supplement companies. That means we can report on the benefits, risks, and alternatives to prescription and over-the-counter drugs free from corporate pressure or influence.

trigger